Third-generation long-acting β 2-adrenoceptor agonists: Medicinal chemistry strategies employed in the identification of once-daily inhaled β 2-adrenoceptor agonists

Future Medicinal Chemistry

Volumn 3, Issue 13, 2011, Pages 1607-1622

  Jacobsen, John R ^a  

^a THERAVANCE INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETIC ACID DERIVATIVE; ADRENALIN; BETA 2 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CARMOTEROL; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; FORMOTEROL; INDACATEROL; INDOLE DERIVATIVE; ISOPRENALINE; LAS 100977; MILVETEROL; OLADATEROL; PF 610355; SALBUTAMOL; SALIGENIN; SALMETEROL; SIBENADET; SOTALOL; UNCLASSIFIED DRUG; VILANTEROL; ZINTEROL;

ASTHMA; CARDIOTOXICITY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENCY; DRUG RECEPTOR BINDING; HUMAN; LIPOPHILICITY; NONHUMAN; PHYSICAL CHEMISTRY; PKA; PRIORITY JOURNAL; RECEPTOR AFFINITY; REVIEW; STEREOCHEMISTRY; STRUCTURE ACTIVITY RELATION; TACHYPHYLAXIS;

ADMINISTRATION, INHALATION; ADRENERGIC BETA-AGONISTS; HUMANS; RECEPTORS, ADRENERGIC, BETA-2;

EID: 80053199542     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.11.116     Document Type: Review

References (79)

1. Waldeck B. β-adrenoceptor agonists and asthma-100 years of development. Eur. J. Pharmacol. 445(1,2), 1-12 (2002). (Pubitemid 34632676)
2. Ahrens RC. Skeletal muscle tremor and the influence of adrenergic drugs. J. Asthma 27(1), 11-20 (1990). (Pubitemid 20104868)
3. Anderson PJ. History of aerosol therapy: liquid nebulization to MDIs to DPIs. Respir. Care 50(9), 1139-1150 (2005).
4. Sanders M. Inhalation therapy: an historical review. Prim. Care Respir. J. 16(2), 71-81 (2007). (Pubitemid 46698770)
5. Dolovich MB, Dhand R. Aerosol drug delivery: developments in device design and clinical use. Lancet 377(9770), 1032-1045 (2011).
6. Byron PR. Drug delivery devices: issues in drug development. Proc. Am. Thorac. Soc. 1(4), 321-328 (2004).
7. Ahrens RC, Smith GD. Albuterol: an adrenergic agent for use in the treatment of asthma. Pharmacology, pharmacokinetics and clinical use. Pharmacotherapy 4(3), 105-121 (1984). (Pubitemid 14075131)
8. Cazzola M, Matera MG. Novel long-acting bronchodilators for COPD and asthma. Br. J. Pharmacol. 155(3), 291-299 (2008).
9. 2-adrenoceptor agonists: current and future direction. Br. J. Pharmacol. 163(1), 4-17 (2011).
10. 2-selectivity of TA-2005, a newly developed bronchodilating agent, in isolated guinea pig tissues. Jpn J. Pharmacol. 57(2), 175-185 (1991).
11. 2-agonists. Biol. Pharm. Bull. 17(8), 1047-1052 (1994). (Pubitemid 24276338)
12. 2-agonist carmoterol following 7 days once daily dosing: comparison with twice daily formoterol in patient with persistent asthma [Abstract]. Eur. Respir. J. 28, 665s- (2006).
13. 2-agonist, in patients with COPD. Am. J. Respir. Crit. Care Med. 177, A655 (2008).
14. 2-adrenoceptor agonists. J. Med. Chem. 46(15), 3210-3220 (2003). (Pubitemid 36842407)
15. 2-agonist in humans. Circulation 79(1), 107-115 (1989). (Pubitemid 19043681)
16. 2-adrenoceptor agonists with a long duration of action. Bioorg. Med. Chem. Lett. 19(17), 5237-5240 (2009).
17. 2 adrenoceptor agonist with a 24 h duration of action. J. Pharmacol. Exp. Ther. 317(2), 762-770 (2006).
18. Charlton SJ. Agonist efficacy and receptor desensitization: from partial truths to a fuller picture. Br. J. Pharmacol. 158(1), 165-168 (2009).
19. Johnson M. The β-adrenoceptor. Am. J. Respir. Crit. Care Med. 158(5, Pt 3), S146-S153 (1998).
20. Clark RB, Knoll BJ, Barber R. Partial agonists and G protein-coupled receptor desensitization. Trends Pharmacol. Sci. 20(7), 279-286 (1999). (Pubitemid 29301681)
21. 2-adrenoceptor agonist. J. Med. Chem. 53(9), 3675-3684 (2010).
22. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 23(1-3), 3-25 (1997). (Pubitemid 27046991)
23. Gleeson MP, Hersey A, Montanari D, Overington J. Probing the links between in vitro potency, ADMET and physicochemical parameters. Nat. Rev. Drug Discov. 10(3), 197-208 (2011).
24. Hitchcock SA, Pennington LD. Structure-brain exposure relationships. J. Med. Chem. 49(26), 7559-7583 (2006). (Pubitemid 46033646)
25. O'Shea R, Moser HE. Physicochemical properties of antibacterial compounds: implications for drug discovery. J. Med. Chem. 51(10), 2871-2878 (2008). (Pubitemid 351706014)
26. Ritchie TJ, Luscombe CN, Macdonald SJF. Analysis of the calculated physicochemical properties of respiratory drugs: can we design for inhaled drugs yet? J. Chem. Inf. Model. 49(4), 1025-1032 (2009).
27. 2-adrenoreceptor agonists for inhaled once-daily treatment of asthma and chronic obstructive pulmonary disease that utilize a sulfonamide agonist headgroup. J. Med. Chem. 53(18), 6640-6652 (2010).
28. Patton JS, Byron PR. Inhaling medicines: delivering drugs to the body through the lungs. Nat. Rev. Drug Discov. 6(1), 67-74 (2007). (Pubitemid 46020287)
29. Agoram BM, Milligan PA, van der Graaf PH. A non-parametric method to analyse time-course of effect in the absence of pharmacokinetic data: Application to inhaled bronchodilators. Eur. J. Pharm. Sci. 34(4-5), 250-256 (2008).
30. 2-adrenoceptor agonist salmeterol. Br. J. Pharmacol. 158(1), 183-194 (2009).
31. 2-adrenoceptor agonists. Trends Pharmacol. Sci. 17(9), 324-330 (1996). (Pubitemid 26302709)
32. 2- adrenoceptor. Pulm. Pharmacol. Ther. 24(2), 247-255 (2011).
33. Anderson GP, Linden A, Rabe KF. Why are long-acting β-adrenoceptor agonists long-acting? Eur. Respir. J. 7(3), 569-578 (1994). (Pubitemid 24099018)
34. 2- adrenergic receptor. J. Biol. Chem. 271(39), 24029-24035 (1996).
35. 2-adrenoceptor activity. Bioorg. Med. Chem. Lett. 14(18), 4705-4710 (2004). (Pubitemid 39490293)
36. Tronde A, Norden B, Marchner H, Wendel AK, Lennernaes H, Bengtsson UH. Pulmonary absorption rate and bioavailability of drugs in vivo in rats: Structure-absorption relationships and physicochemical profiling of inhaled drugs. J. Pharm. Sci. 92(6), 1216-1233 (2003). (Pubitemid 36676468)
37. 2-adrenoceptor agonists as inhaled long-acting bronchodilators. Bioorg. Med. Chem. Lett. 20(17), 5302-5307 (2010).
38. Bennett JA, Tattersfield AE. Time course and relative dose potency of systemic effects from salmeterol and salbutamol in healthy subjects. Thorax 52(5), 458-464 (1997). (Pubitemid 27278145)
39. Guhan AR, Cooper S, Oborne J, Lewis S, Bennett J, Tattersfield AE. Systemic effects of formoterol and salmeterol: a dose-response comparison in healthy subjects. Thorax 55(8), 650-656 (2000). (Pubitemid 30468219)
40. 2 adrenergic receptor agonists incorporating arylsulfonamide groups. J. Med. Chem. 52(8), 2280-2288 (2009).
41. 2- adrenoreceptor agonists. Bioorg. Med. Chem. Lett. 17(14), 4012-4015 (2007). (Pubitemid 46920925)
42. Pilcer G, Amighi K. Formulation strategy and use of excipients in pulmonary drug delivery. Int. J. Pharm. 392(1-2), 1-19 (2010).
43. 2 adrenergic receptor agonists incorporating metabolic inactivation: an antedrug approach. J. Med. Chem. 53(11), 4522-4530 (2010).
44. 2-adrenoceptor agonist with a 24 h bronchodilatory efficacy. Bioorg. Med. Chem. Lett. 20(4), 1410-1414 (2010).
45. Bodor N, Buchwald P. Soft drug design: general principles and recent applications. Med. Res. Rev. 20(1), 58-101 (2000). (Pubitemid 30027561)
46. Bodor N, Buchwald P. Recent advances in retrometabolic drug design (RMDD) and development. Pharmazie 65(6), 395-403 (2010).
47. Bodor N, Buchwald P. Corticosteroid design for the treatment of asthma: structural insights and the therapeutic potential of soft corticosteroids. Curr. Pharm. Des. 12(25), 3241-3260 (2006). (Pubitemid 44375467)
48. 2 agonists. Thorax 51(10), 1051-1056 (1996). (Pubitemid 26360184)
49. 2- agonists. Is there cause for concern? Drug Saf. 16(5), 295-308 (1997). (Pubitemid 27268140)
50. Lipworth B, Tan S, Devlin M, Aiken T, Baker R, Hendrick D. Effects of treatment with formoterol on bronchoprotection against methacholine. Am. J. Med. 104(5), 431-438 (1998). (Pubitemid 28274846)
51. Kelly E, Bailey CP, Henderson G. Agonist-selective mechanisms of GPCR desensitization. Br. J. Pharmacol. 153(Suppl 1), S379-S388 (2008). (Pubitemid 351340999)
52. 2-adrenergic receptor function, response, and regulation. J. Allergy Clin. Immunol. 117(1), 18-24 (2006). (Pubitemid 43017132)
53. 2- adrenergic receptor phosphorylation and internalization. Am. J. Respir. Cell Mol. Biol. 36(2), 254-261 (2007). (Pubitemid 46233479)
54. 2-adrenoceptor responses in human airway cells during prolonged exposure. Br. J. Pharmacol. 158(1), 169-179 (2009).
55. Evans BA, Sato M, Sarwar M, Hutchinson DS, Summers RJ. Ligand-directed signalling at β-adrenoceptors. Br. J. Pharmacol. 159(5), 1022-1038 (2010).
56. Patil PN, Li C, Kumari V, Hieble JP. Analysis of efficacy of chiral adrenergic agonists. Chirality 20(3/4), 529-543 (2008). (Pubitemid 351303994)
57. Page CP, Morley J. Contrasting properties of albuterol stereoisomers. J. Allergy Clin. Immunol. 104(2, Pt. 2), S31-S41 (1999). (Pubitemid 29426707)
58. Cazzola M, Hanania NA, Matera MG. Arformoterol tartrate in the treatment of COPD. Expert Rev. Respir. Med. 4(2), 155-162 (2010).
59. Barnes PJ. Treatment with (R)-albuterol has no advantage over racemic albuterol. Am. J. Respir. Crit. Care Med. 174(9), 969-972 (2006).
60. 2-adrenoceptor agonists for the treatment of asthma and COPD. Bioorg. Med. Chem. Lett. 17(22), 6188-6191 (2007). (Pubitemid 47552833)
61. 2-adrenergic receptor agonists. Bioorg. Med. Chem. 18(2), 728-736 (2010).
62. 2-adrenoceptor agonists. Molecules 14(11), 4486-4496 (2009).
63. Patny A, Desai PV, Avery MA. Homology modeling of G-protein-coupled receptors and implications in drug design. Curr. Med. Chem. 13(14), 1667-1691 (2006). (Pubitemid 43821698)
64. Rosenbaum DM, Rasmussen SGF, Kobilka BK. The structure and function of G-protein-coupled receptors. Nature 459(7245), 356-363 (2009).
65. 2-adrenergic G protein-coupled receptor. Science 318(5854), 1258-1265 (2007). (Pubitemid 350172884)
66. 2 adrenergic G-protein-coupled receptor. Nature 450(7168), 383-387 (2007). (Pubitemid 350126755)
67. 2-Adrenergic Receptor Function. Science 318(5854), 1266-1273 (2007). (Pubitemid 350172885)
68. 2-adrenergic receptor ligands. Proc. Natl Acad. Sci. USA. 106(16), 6843-6848 (2009).
69. 2 adrenergic receptor. J. Med. Chem. 51(16), 4978-4985 (2008).
70. 2-adrenoceptor agonists. Bioorg. Med. Chem. Lett. 19(23), 6640-6644 (2009).
71. 2 adrenoceptor. Nature 469(7329), 175-180 (2011).
72. 2 adrenoceptor complex. Nature 469(7329), 236-240 (2011).
73. 2 -adrenoceptor agonist (LABA).Prog. Respir. Res. 39, 27-31 (2010).
74. Hui CKM, Chung KF. Indacaterol: pharmacologic profile, efficacy and safety in the treatment of adults with COPD. Expert Rev. Respir. Med. 5(1), 9-16 (2011).
75. 2-adrenoreceptor agonists. Bioorg. Med. Chem. Lett. 18(4), 1280-1283 (2008). (Pubitemid 351226549)
76. Manchee GR, Barrow A, Kulkarni S et al. Disposition of salmeterol xinafoate in laboratory animals and humans. Drug Metab. Dispos. 21(6), 1022-1028 (1993). (Pubitemid 23348338)
77. 2-adrenoreceptor agonists. Bioorg. Med. Chem. Lett. 21(5), 1545-1548 (2011).
78. Fitzgerald MF, Fox JC. Emerging trends in the therapy of COPD: Bronchodilators as mono- and combination therapies. Drug Discov. Today 12(11 & 12), 472-478 (2007). (Pubitemid 46795590)
79. 2-adrenoceptor agonists for the treatment of airway diseases. 1. Discovery and biological evaluation of some 7-(2-aminoethyl)-4- hydroxybenzothiazol- 2(3H)-one analogs. J. Med. Chem. 41(25), 4915-4917 (1998). (Pubitemid 28555448)